IL283687A - usp19 inhibitors and their use for therapeutic purposes - Google Patents

usp19 inhibitors and their use for therapeutic purposes

Info

Publication number
IL283687A
IL283687A IL283687A IL28368721A IL283687A IL 283687 A IL283687 A IL 283687A IL 283687 A IL283687 A IL 283687A IL 28368721 A IL28368721 A IL 28368721A IL 283687 A IL283687 A IL 283687A
Authority
IL
Israel
Prior art keywords
therapy
usp19
inhibitors
usp19 inhibitors
Prior art date
Application number
IL283687A
Other languages
English (en)
Hebrew (he)
Inventor
James Samuel Shane Rountree
Peter Hewitt
Mary Melissa Mcfarland
Frank Burkamp
Christina Bell
Colin O'dowd
Timothy Harrison
Matthew Duncan Helm
Ewelina Rozyka
Aaron Cranston
Xavier Jacq
Lauren Proctor
Original Assignee
Almac Discovery Ltd
James Samuel Shane Rountree
Peter Hewitt
Mary Melissa Mcfarland
Frank Burkamp
Christina Bell
Odowd Colin
Timothy Harrison
Matthew Duncan Helm
Ewelina Rozyka
Aaron Cranston
Xavier Jacq
Lauren Proctor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1819936.4A external-priority patent/GB201819936D0/en
Priority claimed from GBGB1904341.3A external-priority patent/GB201904341D0/en
Application filed by Almac Discovery Ltd, James Samuel Shane Rountree, Peter Hewitt, Mary Melissa Mcfarland, Frank Burkamp, Christina Bell, Odowd Colin, Timothy Harrison, Matthew Duncan Helm, Ewelina Rozyka, Aaron Cranston, Xavier Jacq, Lauren Proctor filed Critical Almac Discovery Ltd
Publication of IL283687A publication Critical patent/IL283687A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL283687A 2018-12-06 2021-06-03 usp19 inhibitors and their use for therapeutic purposes IL283687A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1819936.4A GB201819936D0 (en) 2018-12-06 2018-12-06 Therapeutic methods
GBGB1904341.3A GB201904341D0 (en) 2019-03-28 2019-03-28 Therapeutic methods
PCT/GB2019/053456 WO2020115500A1 (en) 2018-12-06 2019-12-06 Usp19 inhibitors for use in therapy

Publications (1)

Publication Number Publication Date
IL283687A true IL283687A (en) 2021-07-29

Family

ID=68887434

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283687A IL283687A (en) 2018-12-06 2021-06-03 usp19 inhibitors and their use for therapeutic purposes

Country Status (12)

Country Link
US (1) US20220016115A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890737B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022510700A (cg-RX-API-DMAC7.html)
KR (1) KR20210100127A (cg-RX-API-DMAC7.html)
CN (1) CN113395965A (cg-RX-API-DMAC7.html)
AU (1) AU2019393161A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021010645A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121422A1 (cg-RX-API-DMAC7.html)
IL (1) IL283687A (cg-RX-API-DMAC7.html)
MX (1) MX2021006542A (cg-RX-API-DMAC7.html)
SG (1) SG11202105911PA (cg-RX-API-DMAC7.html)
WO (1) WO2020115500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134564A1 (en) * 2019-05-06 2020-11-12 Lawrence Marcin Inhibiting usp19
GB202104097D0 (en) * 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds
GB202311227D0 (en) 2023-07-21 2023-09-06 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2009072643A1 (en) 2007-12-03 2009-06-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
CN104174021A (zh) * 2013-05-22 2014-12-03 复旦大学附属华山医院 蛋白酶体抑制剂在制备治疗慢性低度炎症性疾病药物中的用途
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
AU2018342089B2 (en) * 2017-09-26 2024-07-11 Dana-Farber Cancer Institute, Inc. Novel USP7 inhibitors for treating multiple myeloma
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
WO2020115500A1 (en) 2020-06-11
AU2019393161A1 (en) 2021-06-17
EP3890737A1 (en) 2021-10-13
EP3890737B1 (en) 2024-06-05
CA3121422A1 (en) 2020-06-11
MX2021006542A (es) 2021-07-07
BR112021010645A2 (pt) 2021-08-17
KR20210100127A (ko) 2021-08-13
US20220016115A1 (en) 2022-01-20
CN113395965A (zh) 2021-09-14
SG11202105911PA (en) 2021-07-29
JP2022510700A (ja) 2022-01-27

Similar Documents

Publication Publication Date Title
SG11202105747XA (en) Csf1r inhibitors for use in treating cancer
SG11202104356VA (en) Bt1718 for use in treating cancer
IL269462B (en) mdm2 inhibitors and therapeutic methods using them
SG10201913331VA (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
IL282350A (en) Bernani-RGMC inhibitors and their use
IL251618A0 (en) Combined treatment including ox40 binding agonists and tigit inhibitors
SI3806898T1 (sl) Antagonist Gremlin-1 za uporabo pri zdravljenju raka
HUE070659T2 (hu) KDM1A inhibitor és annak felhasználása terápiában
GB201702160D0 (en) Inhibitors for use in therapy
EP3313514A4 (en) POSITIONING DEVICE FOR USE IN THERAPEUTIC TREATMENT
HUE068702T2 (hu) Konjugált antiszensz vegyületek terápiában való alkalmazásra
IL284053A (en) New compounds and their use in therapy
IL288728A (en) Anti-sortilin antibodies for use in therapy
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
ZA202000904B (en) Mpo inhibitors for use in medicine
PL3293201T3 (pl) Łączenie adenowirusa i inhibitorów punktów kontrolnych do leczenia nowotworu
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
GB201821147D0 (en) Mirna for use in therapy
GB201615844D0 (en) Agents for use in therapy
EP4670683A3 (en) SURGICAL APPARATUS
HK40052012A (en) Usp19 inhibitors for use in therapy
GB201908884D0 (en) Inhibitors and use
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
GB201503053D0 (en) Apparatus for use in magnetic hyperthermia treatments